Several other analysts have also weighed in on the stock. Berenberg Bank reiterated a “buy” rating on shares of Evotec AG in a research note on Wednesday, May 10th. Deutsche Bank AG reissued a “neutral” rating on shares of Evotec AG in a research report on Wednesday, May 3rd.
Evotec AG (NASDAQ:EVTCY)‘s stock had its “sell” rating reissued by equities research analysts at DZ Bank AG in a note issued to investors on Monday.
Shares of Evotec AG (NASDAQ:EVTCY) opened at 27.70 on Monday. The company’s 50 day moving average is $30.50 and its 200-day moving average is $23.11. The company has a market capitalization of $1.94 billion and a P/E ratio of 46.95. Evotec AG has a 1-year low of $9.18 and a 1-year high of $33.13.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.